ATE347908T1 - Vorbeugung von gewebeadhäsion - Google Patents

Vorbeugung von gewebeadhäsion

Info

Publication number
ATE347908T1
ATE347908T1 AT03702560T AT03702560T ATE347908T1 AT E347908 T1 ATE347908 T1 AT E347908T1 AT 03702560 T AT03702560 T AT 03702560T AT 03702560 T AT03702560 T AT 03702560T AT E347908 T1 ATE347908 T1 AT E347908T1
Authority
AT
Austria
Prior art keywords
post
operative
adhesions
prevention
formation
Prior art date
Application number
AT03702560T
Other languages
English (en)
Inventor
Philippe Koninckx
Peter Carmeliet
Desire Collen
Sanabria Carlos Roger Molinas
Original Assignee
Vlaams Interuniv Inst Biotech
Thromb X
Leuven K U Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201983A external-priority patent/GB2384428A/en
Priority claimed from GB0202379A external-priority patent/GB2384706A/en
Priority claimed from GB0225128A external-priority patent/GB0225128D0/en
Application filed by Vlaams Interuniv Inst Biotech, Thromb X, Leuven K U Res & Dev filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE347908T1 publication Critical patent/ATE347908T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/13Decoys
AT03702560T 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion ATE347908T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201983A GB2384428A (en) 2002-01-29 2002-01-29 Inhibitors of HIF
GB0202379A GB2384706A (en) 2002-02-04 2002-02-04 Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
GB0225128A GB0225128D0 (en) 2002-10-29 2002-10-29 Laparoscopy and adhesion formation

Publications (1)

Publication Number Publication Date
ATE347908T1 true ATE347908T1 (de) 2007-01-15

Family

ID=27669901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702560T ATE347908T1 (de) 2002-01-29 2003-01-29 Vorbeugung von gewebeadhäsion

Country Status (5)

Country Link
US (1) US20050163781A1 (de)
EP (1) EP1482975B1 (de)
AT (1) ATE347908T1 (de)
DE (1) DE60310383T2 (de)
WO (1) WO2003063904A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20050049309A1 (en) * 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
JP2007515966A (ja) 2003-12-23 2007-06-21 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 疾患の併用療法のための組成物および方法
WO2006026485A2 (en) * 2004-08-25 2006-03-09 Isis Pharmaceuticals, Inc. Modulation of hif1-beta expression
MX2007011735A (es) 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
WO2009020119A1 (ja) * 2007-08-06 2009-02-12 Senju Pharmaceutical Co., Ltd. HIF-1αおよびHIF-2α発現阻害物質含有医薬
EP2785739B1 (de) 2011-12-01 2017-03-15 ThromboGenics N.V. Verbesserung eines augendrucksenkungsergebnisses
ES2851386T3 (es) * 2013-12-18 2021-09-06 Csl Ltd Método de tratamiento de las heridas
EP3426685A1 (de) 2016-03-10 2019-01-16 Oxurion NV Hintere okularfibrosehemmung durch antagonisierung des plazentalen wachstumsfaktors
CA3019841A1 (en) * 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the prevention and treatment of surgical adhesions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887076A3 (de) * 1997-05-07 1999-03-31 Saturnus A.G. Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US7173038B1 (en) * 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation

Also Published As

Publication number Publication date
EP1482975B1 (de) 2006-12-13
EP1482975A2 (de) 2004-12-08
DE60310383D1 (de) 2007-01-25
WO2003063904A2 (en) 2003-08-07
WO2003063904A3 (en) 2004-01-15
DE60310383T2 (de) 2007-09-20
US20050163781A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
DE60310383D1 (de) Vorbeugung von gewebeadhäsion
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
NO20055305L (no) Pyrrolopyridin-2-karboksylsyreamid-inhibitorer av glykogenfosforylase
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE464889T1 (de) Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BRPI0311323B8 (pt) composto inibidor de c-aril glicosídeo sglt2, composição farmacêutica e combinação
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
DE69839877D1 (de) Behandlung und vorbeugung von adhesionen
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
ATE384058T1 (de) Thiazolderivate
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
MX2009004049A (es) Nuevos derivados de fluoreno, composiciones que los contienen y sus usos como inhibidores de la proteina chaperona hsp90.
SE0002739D0 (sv) New use
FI963264A0 (fi) Tromboksaani A2-välitteisten sairauksien ennaltaestoon ja hoitoon tarkoitettu aine
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
PA8605401A1 (es) Derivados de 2-aminobenzoilo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties